Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma

Yang, Zijian; Suda, Goki; Maehara, Osamu et al.

Cancers, 2022, 14(1), 232

Permalink : https://hdl.handle.net/2115/84259

このアイテムのアクセス数:396件（2026-03-08 01:22 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.3390/cancers14010232     2

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
metadata only access
URI
https://hdl.handle.net/2115/84259
タイトル
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
著者
Yang, Zijian ; Suda, Goki ; Maehara, Osamu ; Ohara, Masatsugu ; Yoshida, Sonoe ; Hosoda, Shunichi ; Kimura, Megumi ; Kubo, Akinori ; Tokuchi, Yoshimasa ; Fu, Qingjie ; Yamada, Ren ; Kitagataya, Takashi ; Suzuki, Kazuharu ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Ohnishi, Shunsuke ; Sakamoto, Naoya
著者名
Yang, Zijian
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Maehara, Osamu
著者名
Ohara, Masatsugu
著者名
Yoshida, Sonoe
著者名
Hosoda, Shunichi
著者名
Kimura, Megumi
著者名
Kubo, Akinori
著者名
Tokuchi, Yoshimasa
著者名
Fu, Qingjie
著者名
Yamada, Ren
著者名
Kitagataya, Takashi
著者名
Suzuki, Kazuharu
著者名
Kawagishi, Naoki
著者名
Nakai, Masato
著者名
Sho, Takuya
著者名
Natsuizaka, Mitsuteru
著者名
Morikawa, Kenichi
著者名
Ogawa, Koji
著者名
Ohnishi, Shunsuke
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
キーワード
post progressive survival
lenvatinib
HCC
growth factors
prognosis
発行日
2022-01-04
出版者
MDPI
収録物名
Cancers
巻(号)
14(1)
ページ
232
抄録
Simple Summary In this study, we firstly revealed that the pattern of developing resistance to lenvatinib varies and determines the prognosis of patients with unresectable hepatocellular carcinoma (HCC) by analyzing the changes in growth factors during lenvatinib for unresctable HCC. The evaluation of changes in growth factors during lenvatinib could predict treatment response and PPS and could be used for the determination of salvage therapy. Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3390/cancers14010232